Antituberculosis drug resistance patterns in adults with tuberculous meningitis: Results of haydarpasa-iv study

Simple item page
dc.contributor.authorSenbayrak S.
dc.contributor.authorOzkutuk N.
dc.contributor.authorErdem H.
dc.contributor.authorJohansen I.S.
dc.contributor.authorCivljak R.
dc.contributor.authorInal A.S.
dc.contributor.authorKayabas U.
dc.contributor.authorKursun E.
dc.contributor.authorElaldi N.
dc.contributor.authorSavic B.
dc.contributor.authorSimeon S.
dc.contributor.authorYilmaz E.
dc.contributor.authorDulovic O.
dc.contributor.authorOzturk-Engin D.
dc.contributor.authorCeran N.
dc.contributor.authorLakatos B.
dc.contributor.authorSipahi O.R.
dc.contributor.authorSunbul M.
dc.contributor.authorYemisen M.
dc.contributor.authorAlabay S.
dc.contributor.authorBeovic B.
dc.contributor.authorUlu-Kilic A.
dc.contributor.authorCag Y.
dc.contributor.authorCatroux M.
dc.contributor.authorInan A.
dc.contributor.authorDragovac G.
dc.contributor.authorDeveci O.
dc.contributor.authorTekin R.
dc.contributor.authorGul H.C.
dc.contributor.authorSengoz G.
dc.contributor.authorAndre K.
dc.contributor.authorHarxhi A.
dc.contributor.authorHansmann Y.
dc.contributor.authorOncu S.
dc.contributor.authorKose S.
dc.contributor.authorOncul O.
dc.contributor.authorParlak E.
dc.contributor.authorSener A.
dc.contributor.authorYilmaz G.
dc.contributor.authorSavasci U.
dc.contributor.authorVahaboglu H.
dc.date.accessioned2024-07-22T08:12:45Z
dc.date.available2024-07-22T08:12:45Z
dc.date.issued2015
dc.description.abstractBackground: Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM. Methods: Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested for susceptibility to first-line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB). Results: Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibiting monoresistance to INH, and 40 % in cases with MDR-TBM. In compared to patients without resistance to any first-line drug, the relative risk of death for INH-monoresistance and MDR-TBM was 1.60 (95 % CI, 0.38-6.82) and 2.14 (95 % CI, 0:34-13:42), respectively. Conclusion: INH-resistance and MDR rates seemed not to be worrisome in our study. However, considering their adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for designing anti-TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibility testing. © 2015 Senbayrak et al.
dc.identifier.DOI-ID10.1186/s12941-015-0107-z
dc.identifier.issn14760711
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16170
dc.language.isoEnglish
dc.publisherBioMed Central Ltd.
dc.rightsAll Open Access; Gold Open Access
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntitubercular Agents
dc.subjectCerebrospinal Fluid
dc.subjectDrug Resistance, Bacterial
dc.subjectEurope
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMycobacterium tuberculosis
dc.subjectPrevalence
dc.subjectRetrospective Studies
dc.subjectSurvival Analysis
dc.subjectTuberculosis, Meningeal
dc.subjectYoung Adult
dc.subjectethambutol
dc.subjectisoniazid
dc.subjectrifampicin
dc.subjectstreptomycin
dc.subjecttuberculostatic agent
dc.subjecttuberculostatic agent
dc.subjectadult
dc.subjectArticle
dc.subjectbacterial strain
dc.subjectbacterium culture
dc.subjectbacterium isolate
dc.subjectcerebrospinal fluid
dc.subjectcontrolled study
dc.subjectdrug sensitivity
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmortality
dc.subjectmulticenter study
dc.subjectmultidrug resistant tuberculosis
dc.subjectMycobacterium tuberculosis
dc.subjectretrospective study
dc.subjectrisk factor
dc.subjecttuberculous meningitis
dc.subjectadolescent
dc.subjectaged
dc.subjectantibiotic resistance
dc.subjectclinical trial
dc.subjectdrug effects
dc.subjectEurope
dc.subjectisolation and purification
dc.subjectmicrobiology
dc.subjectmiddle aged
dc.subjectprevalence
dc.subjectsurvival analysis
dc.subjectTuberculosis, Meningeal
dc.subjectvery elderly
dc.subjectyoung adult
dc.titleAntituberculosis drug resistance patterns in adults with tuberculous meningitis: Results of haydarpasa-iv study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu